(LMDX) – Company Press Releases
-
LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th
-
LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
-
LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal
-
LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening Hub
-
LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening Hub
-
LumiraDx Reports Second Quarter 2023 Results
-
LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests
-
LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test
-
LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests
-
LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests
-
LumiraDx Reports First Quarter 2023 Results
-
LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
-
LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
-
LumiraDx Announces Strategic Refocus and Cost Restructuring Program
-
LumiraDx Announces Strategic Refocus and Cost Restructuring Program
-
LumiraDx Reports Fourth Quarter and Full Year 2022 Results
-
LumiraDx Reports Fourth Quarter and Full Year 2022 Results
-
LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21
-
LumiraDx to Present at Raymond James Institutional Investors Conference
-
LumiraDx to Present at Raymond James Institutional Investors Conference
-
LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements
-
LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements
-
LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay
-
LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay
-
LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK
-
LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK
-
LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
-
LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
-
LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test
-
LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test
-
Latest Clinicians’ U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers
-
Latest Clinicians’ U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers
-
Point of Care (POC) Survey Reveals Majority of U.K. Clinicians Endorse Climate Benefits of POC Through Reduction of Carbon Emissions and Anticipate Future Growth of POC Testing to Come from Community
-
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
-
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
-
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
-
LumiraDx Reports Third Quarter 2022 Results
-
LumiraDx Reports Third Quarter 2022 Results
-
LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
-
LumiraDx named by Frost & Sullivan as the 2022 Europe Technology Innovation Leader in the Microfluidics Point of Care Diagnostics Industry
-
LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance
-
LumiraDx Reports Second Quarter 2022 Results
-
LumiraDx Reports Second Quarter 2022 Results
-
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18
-
LumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private Placement
-
LumiraDx Announces Proposed Public Offering of Common Shares
-
LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System
-
LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete
-
LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test
-
LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform
Back to LMDX Stock Lookup
